Innovative, Quality Biomedical Research
Overview of the Year
“Although the IMIM result in the Instituto de Salud Carlos III project call for projects was not as good as other years, IMIM has been able to obtain funding for COVID research projects to a large extent. This highlights the tendency of the institution to continue obtaining European projects and other notable funding, such as CRIS projects.”
Marta López Otero
Head of IMIM Research Department
|Translational Clinical Research||4,736,691.15€|
|Epidemiology and Public Health||3,245,015.35€|
Development of a Therapy for Fragile X Syndrome
The public-private consortium formed by the biotech company Connecta Therapeutics, the Centre for Genomic Regulation (CRG), and the Hospital del Mar Medical Research Institute (IMIM) has received a grant from the Spanish National Innovation Agency to develop an innovative treatment for fragile X syndrome, the most common form of hereditary intellectual disability. In the first phase, CRG will conduct complementary pharmacology studies on the Connecta Therapeutics CTH120 molecule, which preclinical studies found to be a good neuroplasticity modulator. IMIM will then start a Phase I clinical trial.
Tailoring anti-EGFR Therapy in Metastatic Colorectal Cancer: Clonal Dynamics and the Immune System
The project is funded by CRIS Cancer Foundation and the main objective is to better understand the mechanisms of resistance to anti-EGFR treatments in metastatic colorectal tumors. The study aims to characterize the role of immunity and clonal dynamics using liquid biopsy. The project integrates three clinical trials, notably the CITRIC clinical trial that we have recently opened, as well as a preclinical part with in vitro and in vivo models.
eTRANSAFE: Enhancing Translational Safety Assessment through Integrative Knowledge Management
The five-year project coordinated by IMIM aims to develop an advanced data integration infrastructure together with innovative computational methods to improve the security in drug development process. The project is funded by the Innovative Medicines Initiative (IMI2) together with the pharmaceutical industry.
Immune Checkpoints in the Regulation of Natural Killer Cell Responses in Multiple Sclerosis
The project is led by IMIM researchers and funded by Fondo de Investigación Sanitaria. Its main objective is to study the clinical and immunological implications of NK cell regulatory mechanisms based on immune checkpoint inhibitors in multiple sclerosis (PD-1, CTLA-4, TIGIT, Tim-3, NKG2A, Lag3).
MIND/COVID: Mental Health Impact and Needs Associated With COVID-19: A Comprehensive National Evaluation in Spain
The project is led by IMIM researchers and has a team of experts from more than 20 Spanish institutions. Its objective is to study the mental health of healthcare professionals and other vulnerable groups, as well as in patients with COVID-19 and in a sample of the general Spanish adult population. It is funded by the Instituto de Salud Carlos III of the Ministry of Science and Innovation. (FEDER COV20 / 00711)
“Despite the extraordinary impact that the pandemic has had on the activity of our institution, the number of ongoing clinical trials during 2020 has been higher than in previous years, and 150 other new trials have also been signed, demonstrating the tremendous effort made by our researchers.”
Medical Director of Hospital del Mar-Parc de Salut Mar
Clinical Trials Signed in 2020
|Translational Clinical Research||65|
|Other (Hospital and management)||10|
|Epidemiology and Public Health||2|
Clinical Trials, 2016-2020
Relevant Clinical Trials
Fundamental phase-III multicenter, randomized double-blind, placebo-controlled trial with two parallel arms to research the efficacy and safety of human recombinant alkaline phosphatase for the treatment of patients with sepsis-associated acute kidney injury.
Sepsis is the main cause of acute kidney injury and is one of the main causes of death. In fact, patients with sepsis-associated acute kidney injury have high mortality and morbidity and are at risk of developing chronic kidney disease. This trial is based on the administration of alkaline phosphatase in these patients. It is an enzyme present in many cells and organs and has detoxifying effects. The initial results of this clinical trial show that the use of human recombinant alkaline phosphatase increases survival in patients with acute sepsis.
Clara Vilà Vilardell
Open phase Ia/Ib trial on increasing dosage to determine the safety and pharmacokinetics of MTIG7192A in single-drug therapy and in combination with atezolizumab in patients with locally advanced or metastatic tumors.
Phase 1 clinical trial with a novel design to analyze the antitumor activity of a new immunotherapy drug (tiragolumab) in combination with an already approved immunotherapy (atezolizumab) in various solid tumors where immunotherapy is already a standard treatment, with the aim of minimizing the resistance that can appear with this treatment when it is administered in single-drug therapy.
The PENSA Study is a clinical trial aiming at preventing cognitive decline in APOE-ɛ4 carriers with subjective cognitive decline. The proposed clinical trial design evaluates the efficacy of epigallocatechin-3-gallate (EGCG) in the context of a personalized medicine approach including a multimodal intervention looking at improving person-centered outcomes in this population.
Rafa de la Torre
Study of costs associated with the treatment of neovascular age-related macular degeneration (ARMD) in two tertiary hospitals in Spain.
The study is part of a research agreement with Novartis that will make it possible to analyze the use of resources related to the diagnosis and treatment of age-related macular degeneration (ARMD) at Parc de Salut Mar. The study analyzes the number and cost of associated visits and tests and the pharmacologic cost of the treatment. It also links treatment intensity with maintaining visual ability during treatment in the study period: 2017-2018.
This research agreement also includes Hospital Miguel Servet, Zaragoza.
Francesc Cots Reguant
Pere Ortiz Sagristà
“IMIM research programs present major synergies and, above all, remarkable scientific quality. I believe that we are in a very good position so that, in the near future, IMIM will be an undisputed leader in cutting-edge areas of translational biomedical research, both nationally and internationally. I also believe that, because of its intrinsic value and because of the scientific and technological campus that surrounds it, IMIM will be a very powerful pole of attraction for young talent and businesses.”
Xosé R. Bustelo
CSIC Research Professor, Salamanca Cancer Research Center (CSIC-University of Salamanca). Vice-director, Salamanca Cancer Research Center. Coordinator, Mechanisms of Tumor Progression Program of the Spanish Network for Biomedical Research in Cancer (CIBERONC)
Publications by Program
|Translational Clinical Research||296||276|
|Epidemiology and Public Health||225||210|
|Total indexed publications||823||922|
Magri G., Cerutti A.
IgA Summons IgG to Take a Hit at HIV-1. Cell Host Microbe 2020; 27(6): 854-856.
Guinart D, Moreno E, Galindo L, Cuenca-Royo A, Barrera-Conde M, Pérez EJ, Fernández-Avilés C, Correll CU, Canela EI, Casadó V, Cordomí A, Pardo L, de la Torre R, Pérez V, Robledo P.
Altered Signaling in CB1R-5-HT2AR Heteromers in Olfactory Neuroepithelium Cells of Schizophrenia Patients is Modulated by Cannabis Use. Schizophr Bull. 2020 Dec 1;46(6):1547-1557. doi: 10.1093/schbul/sbaa038. PMID: 32249318; PMCID: PMC7846100.
Castañer O, Pintó X, Subirana I, Amor AJ, Ros E, Hernáez Á, Martínez-González MÁ, Corella D, Salas-Salvadó J, Estruch R, Lapetra J, Gómez-Gracia E, Alonso-Gómez AM, Fiol M, Serra-Majem L, Corbella E, Benaiges D, Sorli JV, Ruiz-Canela M, Babió N, Sierra LT, Ortega E, Fitó M.
Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease. J Am Coll Cardiol. 2020 Dec 8;76(23):2712-2724. doi: 10.1016/j.jacc.2020.10.008.
Sentís I, González S, Genescà E, Garcia V, Muiños F, González C, López-Arribillaga E, González J, Fernández-Ibarrondo L, Mularoni L, Espinosa L, Bellosillo B, Ribera JM*, Bigas A*, González-Pérez A, López-Bigas N*.
The evolution of relapse of adult T cell acute lymphoblastic leukemia. Genome Biol 2020; 21(1): 284. *Co-correspondings.
Rodríguez-Espigares I, Torrens M, Tiemann JKS, Aranda D, Ramírez-Anguita JM, Stepniewski T, Worp N, Varela-Rial A, Morales A, Medel B, Pándy-Szekeres G, Mayol E, Giorgino T, Carlsson J, Deupi X, Filipek S, Filizola M, Gómez-Tamayo JC, González A, Gutiérrez-de-Terán H, Jiménez-Rosés M, Jespers W, Kapla J, Khelashvili G, Kolb P, Latek D, Martí-Solano M, Matricon P, Matsoukas MT, Miszta P, Olivella M, Pérez-Benito L, Provasi D, Ríos S, R Torrecilla, Sallander J, Sztyler A, Vasile S, Weinstein H, Zachariae U, Hildebrand PW, De Fabritiis, Sanz F, Gloriam DE, Cordomí A, Guixà-González R, Selent J.
GPCRmd uncovers the dynamics of the 3D-GPCRome. Nat Meth 2020; 17(8): 777-787.
“2020 was like an earthquake, forcing us to adapt rapidly to the new research needs: new sample circuits, new biosafety protocols for transport and for processing COVID-19 patient samples. All of this was done to allow COVID-19 research to proceed without blocking other research requirements. This was a real challenge that has shown us our own capabilities as a core facility.”
Núria Somoza i Abelló
Coordination of IMIM Scientific and Technological Platforms
(30 clinical trials and 107 research projects)
- 42 other services
- 3,174 samples approved
- 1 funding
with samples from MARBiobank
IMIM Internal Facilities
Bioluminescence/Fluorescence Facility (IVIS)
Other PRBB Shared Facilities
“Despite the major difficulties of 2020, fundraising was particularly good. This is mainly due to two aspects: the success of the proposals submitted to the national calls for projects in 2019 and the tremendous ability of our researchers to design and submit proposals of major translational interest to the unexpected COVID-19 calls.”
Deputy Director, IMIM
Sources of Funding
|Public bodies of the Generalitat||1,038,441.86€||1,505,355.87€|
|Other International Grants||1,013,446.11€||975,035.95€|
Non competitive 2019
Non competitive 2020
|Analytics and Quality Control||1,386,412.32€||916,298.07€|
|Courses and congresses||39,840.25€||3,223.14€|
Trustees contribution (Generalitat de Catalunya)
|Trustees contribution (Generalitat de Catalunya)||3,133,333.84€|
Outstanding Competitive Grants
Improving Cognitive Performance in Down Syndrome Patients (ICOD)
Beyond Classical Conditioning: Hippocampal Circuits in Higher-Order Memory Processes (HighMemory)
“One of the priorities of IMIM in order to achieve scientific excellence is attracting talent. In 2020, several actions were taken in this direction: the call for an R4 post, which was open internationally, thorough assessments of candidatures for R3 research posts from public grants to ICREA grants, etc. This has resulted in IMIM taking on two researchers of excellence: Dr. Jana Selent and Dr. Patrick Welz. Furthermore, some very important appointments were made in 2020, such as that of Dr. Anna Bigas, Scientific Director of CIBERONC and Deputy Director of the IJC Preclinical Research Program, and that of Dr. Mar Albà, the new Director of the IMIM Biomedical Informatics Research Program.”
Director of IMIM and Research Director of PSMAR
|Translational Clinical Research||213|
|Epidemiology and Public Health||114|
Researchers by Gender
- Collaborating Researcher
- R4 Leading Researcher
- R3 Established Researcher
- R2 Recognized Researcher
- R1 First Stage Researcher
|R4 Leading Researcher||R3 Established Researcher||R2 Recognized Researcher||R1 First Stage Researcher|
Communication and Public Engagement
“The media and the general public see IMIM as a trustworthy partner. The quality of the institute's communication contents and activities paired with the commitment of its people are highly appreciated by the park and all audiences. For the PRBB, IMIM is an essential and valued ally."
Communication & Business Development. Barcelona Biomedical Research Park (PRBB)
Press Releases With the Greatest Impact
Website and Social Media
For the general public
Support campaigns of Fundació Amics de l’Hospital del Mar for research.
Sempre Endavant (2020)
Crowdfunding campaign to support COVID-19 research
Marina Walktrail (2020)
Nordic walking sports event organized to support the TV3 Marathon on COVID-19 research.